Study Summary
The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
Want to learn more about this trial?
Request More InfoInterventions
Bone Marrow or Peripheral Blood Graft (BMT)PROCEDURE
Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.
Cancer-directed Therapy or Best Supportive CareOTHER
Cancer-directed therapy with intensive regimens ("7+3," Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care.
Frailty AssessmentDIAGNOSTIC_TEST
Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia | Pennsylvania | United States |